Blanco-Melo, D., Nilsson-Payant, B.E., Liu, W.C., Uhl, S., Hoagland, D., Moller, R., Jordan, T.X., Oishi, K., Panis, M., Sachs, D., Wang, T.T., et al. (2020) Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell, 181, 1036- 1045.e9.
https://doi.org/10.1016/j.cell.2020.04.026

has been cited by the following article:

• TITLE: SARS-COV-2 Induce Pulmonary Injury from Basic to Clinical Research

  AUTHORS: Jinguo Zhu

  KEYWORDS: COVID-19, SARS-CoV-2, Pulmonary Injury, Clinical Manifestation, Treatment Strategies

  JOURNAL NAME: World Journal of Cardiovascular Diseases, Vol.12 No.3, March 31, 2022

  ABSTRACT: The SARS-CoV-2 has infected over 194,909,000 cases and over 4,170,000 deaths in the world before the end of July 2021. The virus attacks human alveoli and induces severe lung injury (COVID-19 disease) and spreads rapidly. The mechanisms of COVID-19 disease are unclear. To better understand this disease, This review analyzes the SARS-CoV-2 biological characteristics, insights the effect of alveolar epithelium and its adjacent microvascular endothelium, investigates human host cells immune response and immunothrombosis. Explains clinical manifestations of COVID-19 associated lung injury. It may be helpful for development management strategies for COVID-19 associated pulmonary damage.